The amount of software content within medical devices has grown considerably over recent years and will continue to do so as the level of complexity of medical devices increase. This is driven by the fact that software is introduced to produce sophisticated medical devices that would not be possible using only hardware. This therefore presents opportunities for software development SMEs to become medical device software development organisations. However, some obstacles need to be addressed and overcome in order to make the transition from being a generic software development organisation to becoming a medical device software development organisation. This paper describes these obstacles and how research that is currently being performed within the Regulated Software Research Group in Dundalk Institute of Technology may be used to assist with this transition.
Introduction -Background to Medical Device Software Development
Today software is an increasingly important component of medical devices, as it enables often complex functional changes to be implemented without necessitating changes to the hardware [1] . As a consequence of the increasing demands for greater functionally within medical devices, the complexity of medical device software development also continues to increase [2]. This has resulted in increased demand for appropriate traceability and risk management processes and tools. It is very important that highly effective software development practices are in place within medical device companies due to the safety-critical nature of medical device software. In order to sell their products medical device companies must comply with the regulatory requirements of the countries in which they wish to market their devices [3] . Governments have put in place regulatory bodies to tackle these issues whose role is to define regulatory systems for medical devices and to ensure that only safe medical devices are placed on the market [4] .
While regulatory bodies offer some guidance on what software activities must be performed, no specific method for performing these activities is provided or enforced [5] . In this context in the United States (US), the Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) has published guidance papers which include risk-based activities to be performed during software validation [6] , pre-market submission [7] and when using off-the-shelf software in a medical device [8] . Although the CDRH guidance documents provide information on which software activities should be performed, they do not enforce any specific method for performing these activities. This can result in medical device software companies failing to comply with the expected requirements.
To help address this situation a decision was taken by the medical device industry to recognize ISO/IEC 12207:1995 [9] (a general software engineering lifecycle process standard) as suitable for general medical device software development. Subsequently the Association for the Advancement of Medical Instrumentation (AAMI) software committee carefully reviewed ISO/IEC 12207:1995 and identified a number of shortcomings due to the fact that it was a generic standard. This resulted in the decision to create a new standard which was domain specific to medical device software development. The AAMI did not discard the work done with the ISO/IEC 12207:1995 and used it as the foundation for their new standard "AAMI SW68, Medical device software -Software lifecycle processes" [10] . In 2006, a new standard IEC 62304 [11] was released that was based on the AAMI SW68 standard.
The Council of the European Communities published in 1993 the Directive 93/42/EEC (1993) [12] , the "Medical Device Directive" (MDD), on medical devices. The MDD is intended to ensure the safety of medical devices placed on the market in the European Union (EU), and has the backing of national legislation in member states. The remainder of this paper is structured in the following way. Section 2 considers the reasons why software Small and Medium sized Enterprises (SMEs) are interested in becoming medical device SMEs and the challenges they face. In section 3 recent changes made by the EU and FDA regarding medical device software are discussed. Section 4 outlines the research currently being undertaken by the Regulated Software Research Group (RSRG) in Dundalk Institute of Technology which is of particular value to assist SMEs to develop medical device software. Section 5 discusses what initial steps can be taken by SMEs when embarking on medical device software development. A conclusion is provided in section 6 and future work is outlined.
Why Software SMEs Are Interested in Becoming Medical Device SMEs
Software development SMEs are currently becoming medical device software development SMEs for two main reasons. The first of these is medical devices are becoming increasingly more complex and software facilitates increased functionality without the necessity to replace hardware. Therefore, due to growth in this area for
